Find generic entry opportunities
Anticipate generic drug launch
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of preventing NMDA receptor complex-mediated neuronal damage|
|Abstract:||Disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric-oxide or related redox species, in a concentration effective to effect neuroprotection. Also disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric oxide (or a related redox species such as NO.sup.- or NO.sup.+ equivalent), or a physiologically concentration effective to cause such neuroprotection.|
|Inventor(s):||Lipton; Stuart A. (Newton, MA), Stamler; Jonathan (Chapel Hill, NC)|
|Assignee:||Children's Medical Center Corporation (Boston, MA)|
|Filing Date:||Aug 21, 1998|
|Claims:||1. A method of decreasing NMDA receptor-mediated neuronal damage in a mammal comprising administering to a patient a composition comprising a component selected from the group consisting of: superoxide dismuta se (SOD); an SOD mimic; catalase; combinations of at least two ingredients, said first ingredient being SOD or said mimic and said second ingredient being catalase. |
2. The method of claim wherein said patient is infected with a human immunodeficiency virus (HIV) and said method treats neurological manifestations of HIV infection.
3. The method of claim 1 wherein said patient suffers from amyotrophic lateral sclerosis (ALS) and said method treats neurological manifestations of ALS.
4. The method of claim 1 wherein said patient suffers from neuropathic pain mediated by NMDA receptor activity.
5. The method of any one of claims 1-4, wherein said component is formulated in polyethylene glycol or liposomes to enhance central nervous system absorption and efficacy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.